IDL Biotech has submitted supporting documents to the US FDA (Food and Drug Administration) to be able to obtain future approval of UBC® Rapid, the company’s rapid test for bladder cancer.
Read the press release here (in swedish)
IDL Biotech includes additional clinics in its ongoing multicenter study for UBC® Rapid in Sweden.
IDL Biotech currently has a number of ongoing clinical studies both internationally and in Sweden, with the aim of demonstrating the clinical benefit of UBC® Rapid in bladder cancer and having the test included as a complement in the follow-up of patients with bladder...
